ARA-290 (16mg)

ARA-290 (16mg) is a lyophilized research peptide synthesized, purified, and lyophilized in the USA. Each production batch is purified by repeated rounds of reverse-phase HPLC and identity-confirmed by mass spectrometry.

ARA-290 (16mg) is a focus of tissue-repair research, where it is evaluated for its effects on cellular recovery processes in model systems.

Studies of ARA-290 (16mg) frequently examine signaling cascades linked to structural maintenance and regeneration in vitro.

Researchers studying ARA-290 (16mg) use controlled injury or stress models to observe changes in recovery-related endpoints.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with ARA-290 (16mg). Summaries are provided for orientation only and reflect the cited sources.

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema^[1] — This phase 2 clinical trial evaluated cibinetide (ARA-290) for the treatment of diabetic macular edema. The authors assessed the safety and efficacy of the erythropoietin-derived peptide in this ocular condition. The findings provide clinical data on the tissue-protective actions of ARA-290. (Journal of Clinical Medicine 2020)

Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action^[2] — This study tested the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. The authors examined whether the non-erythropoietic EPO-derived peptide influences emotional processing. The results suggest possible psychotropic effects of ARA-290 that warrant further investigation. (European Neuropsychopharmacology 2015)

References

1. Lois N, Gardner E, McFarland M, et al.. "A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema." Journal of Clinical Medicine. 2020. pmc.ncbi.nlm.nih.gov/articles/PMC7408632/
2. Cerit H, Veer IM, Dahan A, Niesters M, Harmer CJ, Miskowiak KW, Rombouts SARB, Van der Does W. "Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action." European Neuropsychopharmacology. 2015. pubmed.ncbi.nlm.nih.gov/26431906/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.